Jerini to submit a complete response in the next three to four months following the FDA’s not approvable letter for Icatibant in the treatment of acute attacks of hereditary angioedema (HAE)
Filed under: gpcr | Tagged: antagonist, Bradykinin, Bradykinin B2, Firazyr, icatibant, Jerini, regulatory | Leave a Comment »
The FDA has extended the review period for the prasugrel for the treatment of patients with acute coronary syndromes. The drug, codeveloped by Daiichi Sankyo and Lilly was initially granted priority review. The new FDA action date is September 26, 2008.
Filed under: gpcr | Tagged: antagonist, CS-747, CS747, Daiichi-Sankyo, Effient, Lilly, LY-640315, LY640315, P2Y12, prasugrel, Purinoreceptor, R-99224, R99224, regulatory | Leave a Comment »
In this week’s JMC Researchers from the Hungary publish series of mu opioid Endomorphins
Filed under: gpcr | Tagged: agonist, Opioid mu, Preclinical, Research | Leave a Comment »
Astellas has announced the launch of its adenosine 2A receptor agonist, Lexiscan (Regadenoson) Injection, for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The launch triggers a $10 Million Milestone Payment for CV Therapeutics.
Filed under: gpcr | Tagged: Adenosine A2a, agonist, Astellas, cv therapeutics, Lexiscan, Regadenoson | Leave a Comment »
